Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mevalonic Acid SCHEMBL18376074 | 0.79 | HMGCR (0.67) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| Mevalonic Acid SCHEMBL120275 | 0.79 | HMGCR (0.67) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| Mevalonic Acid SCHEMBL120276 | 0.79 | HMGCR (0.67) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| Mevalonic Acid SCHEMBL8854071 | 0.79 | HMGCR (0.67) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| SCHEMBL15703179 | 0.78 | HMGCR (0.38) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| Mevalonic Acid SCHEMBL30657480 | 0.77 | HMGCR (0.64) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| Mevalonic Acid SCHEMBL29654223 | 0.77 | HMGCR (0.64) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| Mevalonic Acid SCHEMBL28016589 | 0.77 | HMGCR (0.64) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| Mevalonic Acid SCHEMBL31294828 | 0.77 | HMGCR (0.64) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| Mevalonic Acid SCHEMBL28016588 | 0.77 | HMGCR (0.64) | HMGCRCHRM1TBXA2RADRA1AFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120093922-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME | AMARIN CORPORATION PLC (IE) | 2012-04-19 | — | — | US | disclosed |
| EP-2424521-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME | Amarin Corporation PLC (IE) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093922-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME | ALOX5, PTGER1, PPARA | HMGCR 52/4885CHRM1 3718/4885TBXA2R 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.